CN105663928A - 一种治疗动物皮肤病的药膏及其制备方法 - Google Patents
一种治疗动物皮肤病的药膏及其制备方法 Download PDFInfo
- Publication number
- CN105663928A CN105663928A CN201610052209.1A CN201610052209A CN105663928A CN 105663928 A CN105663928 A CN 105663928A CN 201610052209 A CN201610052209 A CN 201610052209A CN 105663928 A CN105663928 A CN 105663928A
- Authority
- CN
- China
- Prior art keywords
- ointment
- weight portions
- treatment
- preparation
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 47
- 208000017520 skin disease Diseases 0.000 title claims abstract description 45
- 241001465754 Metazoa Species 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000000284 extract Substances 0.000 claims abstract description 48
- 241000746375 Andrographis Species 0.000 claims abstract description 22
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003639 laurocapram Drugs 0.000 claims abstract description 21
- 229940099259 vaseline Drugs 0.000 claims abstract description 14
- 206010048768 Dermatosis Diseases 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000006071 cream Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 abstract description 15
- 241000282326 Felis catus Species 0.000 abstract description 15
- 208000003251 Pruritus Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 9
- 208000010668 atopic eczema Diseases 0.000 abstract description 7
- 241000233866 Fungi Species 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 208000002474 Tinea Diseases 0.000 abstract description 5
- 241000130764 Tinea Species 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 235000013399 edible fruits Nutrition 0.000 abstract description 5
- 206010011732 Cyst Diseases 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 208000031513 cyst Diseases 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 238000010926 purge Methods 0.000 abstract description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 4
- 238000010792 warming Methods 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 4
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 4
- 240000001851 Artemisia dracunculus Species 0.000 abstract 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 4
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 4
- 239000001138 artemisia absinthium Substances 0.000 abstract 4
- 235000008216 herbs Nutrition 0.000 abstract 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 4
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 2
- 241000238876 Acari Species 0.000 abstract 2
- 241000212948 Cnidium Species 0.000 abstract 2
- 241000972673 Phellodendron amurense Species 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 244000197580 Poria cocos Species 0.000 abstract 2
- 241000219784 Sophora Species 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 241000238631 Hexapoda Species 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 229960001777 castor oil Drugs 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 8
- XVPBINOPNYFXID-LHDUFFHYSA-N Ammothamnine Chemical compound C([C@@H]1CCC[N+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-LHDUFFHYSA-N 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000035617 depilation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000004362 fungal culture Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PIAPWPAWQGDOMN-UHFFFAOYSA-N Kuraridine Natural products COC1=CC(O)=C(CC(CC=C(C)C)C(C)=C)C(O)=C1C(=O)C=CC1=CC=C(O)C=C1O PIAPWPAWQGDOMN-UHFFFAOYSA-N 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 2
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- PIAPWPAWQGDOMN-SXAWMYDMSA-N (e)-1-[2,4-dihydroxy-6-methoxy-3-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]phenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(O)=C(C[C@@H](CC=C(C)C)C(C)=C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1O PIAPWPAWQGDOMN-SXAWMYDMSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000356446 Cnidium monnieri Species 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 235000008314 Echinocereus dasyacanthus Nutrition 0.000 description 1
- 240000005595 Echinocereus dasyacanthus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007157 Hydrophthalmos Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- PIAPWPAWQGDOMN-GOSISDBHSA-N Kuraridin Natural products COc1cc(O)c(C[C@@H](CC=C(C)C)C(=C)C)c(O)c1C(=O)C=Cc2ccc(O)cc2O PIAPWPAWQGDOMN-GOSISDBHSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- VQYBAEAOOJBSTR-QHSBEEBCSA-N Sophoranol Chemical compound C([C@@H]12)CCC(=O)N1C[C@@]1(O)[C@H]3[C@@H]2CCCN3CCC1 VQYBAEAOOJBSTR-QHSBEEBCSA-N 0.000 description 1
- VQYBAEAOOJBSTR-AYRXBEOTSA-N Sophoranol Natural products O=C1N2[C@H]([C@@H]3[C@@H]4[C@](O)(C2)CCCN4CCC3)CCC1 VQYBAEAOOJBSTR-AYRXBEOTSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 201000001024 buphthalmos Diseases 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229930017327 cytisine Natural products 0.000 description 1
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 1
- 229940027564 cytisine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compounds Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000013521 mastic Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗动物皮肤病的药膏,采用穿心莲、黄柏、艾叶、茵陈、苦参提取物、地肤子、土茯苓、蛇床子提取物等多种天然中草药作为原料,辅以月桂氮酮、凡士林、蓖麻油和蜂蜜,穿心莲和黄柏用以清热解毒、泻火、燥湿,艾叶用以理气血,逐寒湿,温经,茵陈、地肤子和土茯苓用以清热利湿,祛风止痒,辅以苦参提取物具有的活血止血功效,蛇床子提取物具有的祛风、杀虫功效,上述诸药协调配伍,相互增益,共同起到消炎消肿、止痛止痒、抑菌抗菌、促进皮肤完善的功效;针对犬猫术的各种皮炎、湿疹、皮肤瘙痒、过敏、癣、螨、无名肿痛有显著疗效,针对犬猫皮肤干燥、皮屑或渗出性皮炎、细菌螨虫、真菌脂溢性皮炎、趾间囊肿或其他皮肤病有辅助治疗作用。
Description
技术领域
本发明属于药膏技术领域,具体涉及一种治疗动物皮肤病的药膏及其制备方法。
背景技术
随着人们生活水平的不断提高,犬、猫等宠物饲养逐渐增加。在喂养的过程中,由于接触传染或间接传染以及宠物主人对宠物的照顾不当,很容易导致宠物患有皮肤疾病。皮肤疾病是指被皮结构的炎症损伤,是犬、猫等宠物的一种常见病。发病率很高,在临床就诊病例中该病占10-30%,而且皮肤病病因多,症状复杂,病程较长,确诊及治疗都有难度。
宠物皮肤疾病以真菌感染为主,症状主要是脱毛、宠物情绪不稳定,而且长期感染真菌后,易感染螨虫和继发细菌感染,造成全身瘙痒和脱毛,严重影响宠物的健康,甚至导致死亡。
目前,针对宠物皮肤病的治疗方式主要以外用药剂为主,辅以注射真菌针剂。临床上多采用克霉唑、酮康唑、癣净、盐酸特比萘酚溶液等抗真菌药物,这些抗真菌药物都有一定毒性,且容易引发抗药性,一般用药时间长达一月甚至数月,长期给药对宠物的健康造成损害。
发明内容
为了解决现有技术存在的上述问题,本发明提供了一种无毒副作用、疗效好、见效快、用药时间短的治疗动物皮肤病的药膏及其制备方法。
本发明所采用的技术方案为:
一种治疗动物皮肤病的药膏,原料组分包括:
穿心莲,20-30重量份;
黄柏,25-35重量份;
艾叶,15-25重量份;
茵陈,10-20重量份;
苦参提取物,1-3重量份;
地肤子,20-30重量份;
土茯苓,10-20重量份;
蛇床子提取物,2-4重量份;
月桂氮酮,5-10重量份。
进一步优选所述的治疗动物皮肤病的药膏的原料组分包括:
穿心莲,25重量份;
黄柏,30重量份;
艾叶,20重量份;
茵陈,15重量份;
苦参提取物,2重量份;
地肤子,25重量份;
土茯苓,15重量份;
蛇床子提取物,3重量份;
月桂氮酮,8重量份。
一种制备所述的治疗动物皮肤病的药膏的方法,包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料加入水进行煎煮,得到煎煮液,所述煎煮液经过滤、浓缩,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入乙醇并混合均匀,静置后,经过滤、浓缩得到浓缩膏,待用;
(4)称取凡士林,加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏。
步骤(1)中,所述各原料粉体的粒径均为80-120目。
步骤(2)中,进行所述煎煮之前,所述混合料在水中进行浸泡3-6小时,所述混合料与水的质量比为1:8-1:12。
步骤(2)中,进行所述煎煮的温度为40-45℃,进行所述煎煮的时间为40-60min;进行所述浓缩的温度为28-35℃,进行所述浓缩的时间为40-90min。
步骤(2)中,所述煎煮重复进行2-3次,所得煎煮液混合均匀即为所述煎煮液。
步骤(3)中,所述浓缩液与所述乙醇的质量之比为2:3-1:1;所述乙醇的体积浓度为80-90%。
步骤(3)中,进行所述浓缩的温度为30-40℃,进行所述浓缩的时间为40-90。
步骤(3)所述浓缩膏的密度为1.1-1.3g/ml。
为了便于理解本发明,下面对本发明中的原料及药效作进一步阐述。
穿心莲,味苦,性寒;清热解毒,泻火,燥湿。主风热感冒,温病发热,肺热咳嗽,百日咳,肺痈,咽喉肿痛,湿热黄疸,淋证,丹毒,疮疡痈肿,湿疹,毒蛇咬伤。用于感冒发热,咽喉肿痛,口舌生疮,顿咳劳嗽,泄泻痢疾,热淋涩痛,痈肿疮疡,毒蛇咬伤。
黄柏,味苦,性寒;清热、燥湿,泻火,解毒。治热痢,泄泻,消渴,黄疸,痿躄,梦遗,淋浊,痔疮,便血,亦白带下,骨蒸劳热,目赤肿痛,口舌生疮,疮疡肿毒。
艾叶,味辛、苦,性温;理气血,逐寒湿,温经,止血,安胎。治心腹冷痛,泄泻转筋,久痢,吐衄,下血,月经不调,崩漏,带下,胎动不安,痈疡,疥癣。
茵陈,味辛、苦,性微寒;清湿热,退黄疸。用于黄疸尿少,湿疮瘙痒;传染性黄疸型肝炎。
苦参提取物,自豆科植物苦参干燥根中提取而得的总生物碱。有效成分:含苦参碱、氧化苦参碱、羟基苦参碱、槐果碱(脱氢苦参碱)、野靛碱等生物碱和苦参醇、苦参啶醇等黄酮类化合物。主要用于活血止血,清肺止咳,治咳血,咯血,肺炎咳嗽,妇女白带。可以提高机体力量和灵活性,能迅速恢复疲劳;调节免疫系统,对大脑和器官功能有双向调节作用。有利尿、平喘、催眠、抗心律失常等作用。
地肤子,味苦,性寒;清热利湿,祛风止痒。主小便不利,淋浊,带下,血痢,风疹,湿疹,疥癣,皮肤瘙痒,疮毒。用于小便涩痛,阴痒带下,风疹,湿疹,皮肤瘙痒。
土茯苓,性平,味甘淡;清热除湿,泄浊解毒,通利关节。主梅毒,淋浊,泄泻,筋骨挛痛,脚气,痈肿,疮癣,瘰疬,瘿瘤及汞中毒。
蛇床子提取物,从伞形科植物蛇床的果实中提取。温肾壮阳,燥湿,祛风,杀虫。用于阳痿宫冷,寒湿带下,湿痹腰痛;外治外阴湿疹,妇人阴痒,滴虫性阴道炎。
月桂氮酮,药用辅料。为无色至微黄色的澄清的油状液体;无臭,几乎无味。用作外用药物涂抹、按摩的促渗剂。
本发明的有益效果为:
1、本发明所述的治疗动物皮肤病的药膏,采用穿心莲、黄柏、艾叶、茵陈、苦参提取物、地肤子、土茯苓、蛇床子提取物等多种天然中草药作为原料,辅以月桂氮酮,穿心莲和黄柏用以清热解毒、泻火、燥湿,艾叶用以理气血,逐寒湿,温经,茵陈、地肤子和土茯苓用以清热利湿,祛风止痒,辅以苦参提取物具有的活血止血功效,蛇床子提取物具有的祛风、杀虫功效,月桂氮酮用以促进皮肤渗透和吸收,上述诸药协调配伍,相互增益,共同起到消炎消肿、止痛止痒、抑菌抗菌、促进皮肤完善的功效;针对犬猫的各种皮炎、湿疹、皮肤瘙痒、过敏、癣、螨、无名肿痛有显著疗效,针对犬猫皮肤干燥、皮屑或渗出性皮炎、细菌、螨虫、真菌脂溢性皮炎、趾间囊肿或其他皮肤病有辅助治疗作用。
2、本发明所述的治疗动物皮肤病的药膏的制备方法,通过将以穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓作为原料,依次进行混合、煎煮、过滤、浓缩得到浓缩液,向所述浓缩液中添加乙醇并进行再次浓缩、过滤得到浓缩膏;之后将所述浓缩膏加入凡士林和蓖麻油的混合物中进行充分混合得到预混料,最后,向所述预混料中依次加入苦参提取物、蛇床子提取物、蜂蜜和月桂氮酮,最终制得所述药膏中,上述各种原料的有效成分得以最大保留,药效得以协同发挥,制备得到药膏具有消炎消肿、止痛止痒、抑菌抗菌、促进皮肤完善的功效,针对犬猫术的各种皮炎、湿疹、皮肤瘙痒、过敏、癣、螨、无名肿痛有显著疗效,针对犬猫皮肤干燥、皮屑或渗出性皮炎、细菌、螨虫、真菌脂溢性皮炎、趾间囊肿或其他皮肤病有辅助治疗作用。
具体实施方式
下面实施例中以1重量份代表1g。
实施例1
本实施例提供一种治疗动物皮肤病的药膏,其原料组分包括:
穿心莲,20重量份;
黄柏,35重量份;
艾叶,15重量份;
茵陈,20重量份;
苦参提取物(西安仁邦生物科技有限公司,CAS号:16837-52-8,生产批号:20141007),1重量份;
地肤子,30重量份;
土茯苓,10重量份;
蛇床子提取物(西安仁邦生物科技有限公司,CAS号:484-12-8,生产批号:20140518),4重量份;
月桂氮酮,5重量份;
凡士林,100重量份;
蓖麻油,30重量份;
蜂蜜,40重量份。
进一步,所述的治疗动物皮肤病的制备方法包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到粒径均为80目上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料加入水并控制所述混合料与水的质量比为1:8,在40℃进行煎煮60min,得到煎煮液,所述煎煮液经过滤、28℃浓缩90min,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入体积浓度为80%乙醇并混合均匀,控制所述浓缩液与所述乙醇的质量之比为2:3;静置后,经过滤、30℃浓缩90min,得到密度为1.1g/ml浓缩膏,待用;
(4)称取凡士林,70℃水浴加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却至55℃,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入所述蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏,装入经消毒灭菌后的容器内保存。
实施例2
本实施例提供一种治疗动物皮肤病的药膏,其原料组分包括:
穿心莲,30重量份;
黄柏,25重量份;
艾叶,25重量份;
茵陈,10重量份;
苦参提取物(西安仁邦生物科技有限公司,CAS号:16837-52-8,生产批号:20141007),3重量份;
地肤子,20重量份;
土茯苓,20重量份;
蛇床子提取物(西安仁邦生物科技有限公司,CAS号:484-12-8,生产批号:20140518),2重量份;
月桂氮酮,10重量份;
凡士林,60重量份;
蓖麻油,40重量份;
蜂蜜,30重量份。
进一步,所述的治疗动物皮肤病的制备方法包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到粒径均为120目上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料中加入水并进行浸泡3小时,之后进行重复煎煮2次;
每次煎煮时,所述混合料与水的质量比均为1:12,每次煎煮的温度均为45℃,每次煎煮的时间均为40min,将2次所得煎煮液混合均匀即为所述煎煮液,所述煎煮液经过滤、35℃浓缩40min,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入体积浓度为90%乙醇并混合均匀,控制所述浓缩液与所述乙醇的质量之比为1:1;静置后,经过滤、40℃浓缩40min,得到密度为1.3g/ml浓缩膏,待用;
(4)称取凡士林,80℃水浴加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却至65℃,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入所述蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏,装入经消毒灭菌后的容器内保存。
实施例3
本实施例提供一种治疗动物皮肤病的药膏,其原料组分包括:
穿心莲,25重量份;
黄柏,30重量份;
艾叶,20重量份;
茵陈,15重量份;
苦参提取物(西安仁邦生物科技有限公司,CAS号:16837-52-8,生产批号:20141007),2重量份;
地肤子,25重量份;
土茯苓,15重量份;
蛇床子提取物(西安仁邦生物科技有限公司,CAS号:484-12-8,生产批号:20140518),3重量份;
月桂氮酮,8重量份;
凡士林,80重量份;
蓖麻油,35重量份;
蜂蜜,35重量份。
进一步,所述的治疗动物皮肤病的制备方法包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到粒径均为100目上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料中加入水并进行浸泡6小时,之后进行重复煎煮3次;
每次煎煮时,所述混合料与水的质量比均为1:10,每次煎煮的温度均为42℃,每次煎煮的时间均为50min,将3次所得煎煮液混合均匀即为所述煎煮液,所述煎煮液经过滤、32℃浓缩60min,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入体积浓度为85%乙醇并混合均匀,控制所述浓缩液与所述乙醇的质量之比为2:3;静置后,经过滤、35℃浓缩60min,得到密度为1.2g/ml浓缩膏,待用;
(4)称取凡士林,75℃水浴加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却至60℃,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入所述蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏,装入经消毒灭菌后的容器内保存。
实施例4
本实施例提供一种治疗动物皮肤病的药膏,其原料组分包括:
穿心莲,22重量份;
黄柏,28重量份;
艾叶,18重量份;
茵陈,18重量份;
苦参提取物(西安仁邦生物科技有限公司,CAS号:16837-52-8,生产批号:20141007),2重量份;
地肤子,22重量份;
土茯苓,12重量份;
蛇床子提取物(西安仁邦生物科技有限公司,CAS号:484-12-8,生产批号:20140518),3重量份;
月桂氮酮,6重量份;
凡士林,70重量份;
蓖麻油,35重量份;
蜂蜜,38重量份。
进一步,所述的治疗动物皮肤病的制备方法包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到粒径均为100目上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料中加入水并进行浸泡5小时,之后进行重复煎煮2次;
每次煎煮时,所述混合料与水的质量比均为1:10,每次煎煮的温度均为42℃,每次煎煮的时间均为45min,将2次所得煎煮液混合均匀即为所述煎煮液,所述煎煮液经过滤、32℃浓缩70min,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入体积浓度为85%乙醇并混合均匀,控制所述浓缩液与所述乙醇的质量之比为2:3;静置后,经过滤、32℃浓缩50min,得到密度为1.2g/ml浓缩膏,待用;
(4)称取凡士林,75℃水浴加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却至60℃,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入所述蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏,装入经消毒灭菌后的容器内保存。
实施例5
本实施例提供一种治疗动物皮肤病的药膏,其原料组分包括:
穿心莲,28重量份;
黄柏,27重量份;
艾叶,22重量份;
茵陈,12重量份;
苦参提取物(西安仁邦生物科技有限公司,CAS号:16837-52-8,生产批号:20141007),2重量份;
地肤子,28重量份;
土茯苓,18重量份;
蛇床子提取物(西安仁邦生物科技有限公司,CAS号:484-12-8,生产批号:20140518),3重量份;
月桂氮酮,8重量份;
凡士林,80重量份;
蓖麻油,38重量份;
蜂蜜,35重量份。
进一步,所述的治疗动物皮肤病的制备方法包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到粒径均为100目上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料中加入水并进行浸泡4小时,之后进行重复煎煮2次;
每次煎煮时,所述混合料与水的质量比均为1:10,每次煎煮的温度均为42℃,每次煎煮的时间均为55min,将2次所得煎煮液混合均匀即为所述煎煮液,所述煎煮液经过滤、30℃浓缩55min,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入体积浓度为85%乙醇并混合均匀,控制所述浓缩液与所述乙醇的质量之比为1:1;静置后,经过滤、35℃浓缩65min,得到密度为1.2g/ml浓缩膏,待用;
(4)称取凡士林,75℃水浴加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却至60℃,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入所述蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏,装入经消毒灭菌后的容器内保存。
本发明所采用的各种中草药原料经检测均不含汞、铅等重金属残留。所述药膏在25℃以上容易变稀,影响使用,疗效不变,夏季可冷藏(2-8℃)保存。
本发明实施例1-5所述的治疗动物外伤的药膏均为淡黄色细腻乳膏,具有冰片辛香味;膏体均匀细腻,无颗粒物,具有适宜的黏稠性,易于涂布,融点42℃左右,微生物限度检查复合中国兽药典有关规定。此外,取金创膏样品10g装入离心管中,以3000r/min-1的转速离心30min,未见分层现象。
实验例
本发明人通过对临床100例具有皮肤疾病的宠物应用该膏剂的观察,其中犬类82例,猫类18例。
应用方法:皮肤清洁后,取适量膏剂涂擦于皮肤患处表面,每日1-2次,视症状增减次数,腺、囊肿挤净后使用。
疗效评定标准:
治愈:临床症状完全消失,68例。
有效:临床症状部分消失,各项体征逐步好转27例。
无效:症状体征无明显改善5例。总有效率95%。
典型临床病例:
1、广东省佛山市顺德区多喜爱宠物医院
佛山市刘某2015年5月4日带一体重29.3kg3英国斗牛犬就诊,临床症状表现面部褶皱有浓汁渗出,恶臭气味,褶皱皮肤边缘出现水肿与红斑,医生通过皮肤刮样镜检,排除螨虫感染,同时做真菌培养检查,结果为阴性,通过仔细检查发现浓汁由皮肤褶皱中渗出,与瘤形成,蠕形螨,脂溢性皮炎鉴别病排除,确诊为皱襞皮肤炎(主要由皮肤间相互摩擦,引起细菌增殖),通过每天用过氧化苯甲酰洗澡,然后局部涂抹实施例1所述药膏,每天一次。2周后康复,叮嘱犬主人需要对斗牛犬减肥,减少皮肤褶皱。
2、河北衡水市爱心宠物医院
衡水市田某2015年6月12日带一体重4.2kg的2岁折耳猫就诊,临床表现皮肤毛干中心,毛囊形成脓疱,有结痂,高色素化,类似牛眼一样的脱毛,皮肤凹凸不平,医生通过直接化验脓疱汁液,细菌培养与抗生素药敏实验检查出有葡萄球菌,活组织检查毛囊中有中性粒细胞渗出,然后真菌培养,刮皮化验排除真菌,螨虫感染。确诊为表层细菌毛囊炎,医生通过7天连续速诺片剂(成分阿莫西林克拉维酸钾)口服,每周用抗菌香波洗澡,治疗期间每天涂抹实施例2所述药膏一次,连续8周,基本康复,此病容易复发,建议主人及时复诊。
3、河南省信阳市华锋动物医院
信阳市周某2015年6月17日带一体重2.8kg的4月龄吉娃娃就诊,临床表现口鼻部,眼周围皮肤,嘴边,头部,耳道、前腿、躯干有脱毛症状,四肢、躯干表现有红斑、色素沉着、鳞屑。医生通过多个部位的皮肤深层刮片检查,发现有蠕形螨,通过每周一次注射多拉菌素注射液,平时配合药浴,涂抹实施例3所述药膏,每天一次,4周时间康复。
4、内蒙古包头市乌兰爱心宠物医院
包头市赵某2015年8月20日带一1.35kg2岁金吉拉猫就诊,临床表现头、颈、腿、躯干,特别是眼睑周围脱毛,有红斑、鳞屑和结痂。瘙痒,耳朵里有耳垢并且有炎症。医生通过皮肤浅层和深层的刮片镜检,耳拭子检查。诊断为猫蠕形螨。医生每周注射多拉菌素,并药浴,每天涂抹实施例4所述药膏一次,2个月后逐渐痊愈。
5、重庆南岸区南山灵动猫舍
重庆市南岸区南山灵动猫舍2015年8月21日,4只猫相继出现瘙痒,不规则或圆形秃毛,伴随鳞屑产生,送至医院诊断检查,通过真菌培养,确定为猫的浅层真菌病,猫舍自己通过注射伊曲康唑,药浴,每日涂抹实施例5所述药膏一次,4-6周后相继康复。
本发明不局限于上述最佳实施方式,任何人在本发明的启示下都可得出其他各种形式的产品,但不论在其形状或结构上作任何变化,凡是具有与本申请相同或相近似的技术方案,均落在本发明的保护范围之内。
Claims (10)
1.一种治疗动物皮肤病的药膏,其特征在于,原料组分包括:
穿心莲,20-30重量份;
黄柏,25-35重量份;
艾叶,15-25重量份;
茵陈,10-20重量份;
苦参提取物,1-3重量份;
地肤子,20-30重量份;
土茯苓,10-20重量份;
蛇床子提取物,2-4重量份;
月桂氮酮,5-10重量份。
2.根据权利要求1所述的治疗动物皮肤病的药膏,其特征在于,原料组分包括:
穿心莲,25重量份;
黄柏,30重量份;
艾叶,20重量份;
茵陈,15重量份;
苦参提取物,2重量份;
地肤子,25重量份;
土茯苓,15重量份;
蛇床子提取物,3重量份;
月桂氮酮,8重量份。
3.一种制备权利要求1或2所述的治疗动物皮肤病的药膏的方法,其特征在于,包括如下步骤:
(1)分别称取穿心莲、黄柏、艾叶、茵陈、地肤子和土茯苓,经分别干燥、粉碎处理后,得到上述各原料粉体,将上述各原料粉体进行充分混合,得到混合料,待用;
(2)向步骤(1)所述混合料加入水进行煎煮,得到煎煮液,所述煎煮液经过滤、浓缩,得到浓缩液;
(3)向步骤(2)所述浓缩液中加入乙醇并混合均匀,静置后,经过滤、浓缩得到浓缩膏,待用;
(4)称取凡士林,加热使其融化后加入蓖麻油,之后加入步骤(3)所得浓缩膏,搅拌使其混合均匀,静置冷却,得到预混料;
(5)向步骤(4)所述预混料中加入所述苦参提取物和蛇床子提取物并进行均匀混合,之后加入蜂蜜和月桂氮酮,搅拌使其混合均匀,即得所述治疗动物皮肤病的药膏。
4.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(1)中,所述各原料粉体的粒径均为80-120目。
5.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(2)中,进行所述煎煮之前,所述混合料在水中进行浸泡3-6小时,所述混合料与水的质量比为1:8-1:12。
6.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(2)中,进行所述煎煮的温度为40-45℃,进行所述煎煮的时间为40-60min;进行所述浓缩的温度为28-35℃,进行所述浓缩的时间为40-90min。
7.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(2)中,所述煎煮重复进行2-3次,所得煎煮液混合均匀即为所述煎煮液。
8.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(3)中,所述浓缩液与所述乙醇的质量之比为2:3-1:1;所述乙醇的体积浓度为80-90%。
9.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(3)中,进行所述浓缩的温度为30-40℃,进行所述浓缩的时间为40-90min。
10.根据权利要求3所述的治疗动物皮肤病的药膏的制备方法,其特征在于,步骤(3)所述浓缩膏的密度为1.1-1.3g/ml。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610052209.1A CN105663928A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗动物皮肤病的药膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610052209.1A CN105663928A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗动物皮肤病的药膏及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105663928A true CN105663928A (zh) | 2016-06-15 |
Family
ID=56303636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610052209.1A Pending CN105663928A (zh) | 2016-01-20 | 2016-01-20 | 一种治疗动物皮肤病的药膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663928A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106063925A (zh) * | 2016-07-22 | 2016-11-02 | 许备占 | 野芙蓉宠物皮肤外用药 |
CN108066518A (zh) * | 2018-02-02 | 2018-05-25 | 青岛农业大学 | 一种犬用中药浴液组合物及其制备方法 |
CN112439087A (zh) * | 2020-11-24 | 2021-03-05 | 华夏瑞天(北京)生物科技有限公司 | 一种猪场的消毒方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876144A (zh) * | 2006-04-24 | 2006-12-13 | 高祝兰 | 一种治疗毛皮动物皮肤病的中药及其制备工艺 |
CN101474284A (zh) * | 2009-01-16 | 2009-07-08 | 重庆灵方生物技术有限公司 | 一种治疗真菌性皮肤病的外用药 |
-
2016
- 2016-01-20 CN CN201610052209.1A patent/CN105663928A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1876144A (zh) * | 2006-04-24 | 2006-12-13 | 高祝兰 | 一种治疗毛皮动物皮肤病的中药及其制备工艺 |
CN101474284A (zh) * | 2009-01-16 | 2009-07-08 | 重庆灵方生物技术有限公司 | 一种治疗真菌性皮肤病的外用药 |
Non-Patent Citations (3)
Title |
---|
江西妙方生物科技有限公司: "藏佛医湿毒清", 《WWW.BIZTX.CN/PRODUCTS/ZSINFO.ASP?ZSID=52725》 * |
牛晓静等: "从脏腑论治身痒验案举隅", 《江西中医药》 * |
苑振亭: "《新编中药400味速查手册》", 30 September 2014, 金盾出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106063925A (zh) * | 2016-07-22 | 2016-11-02 | 许备占 | 野芙蓉宠物皮肤外用药 |
CN108066518A (zh) * | 2018-02-02 | 2018-05-25 | 青岛农业大学 | 一种犬用中药浴液组合物及其制备方法 |
CN112439087A (zh) * | 2020-11-24 | 2021-03-05 | 华夏瑞天(北京)生物科技有限公司 | 一种猪场的消毒方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041173B (zh) | 一种治疗皮炎、湿疹的中药外用制剂及其制备方法 | |
CN105168090A (zh) | 一种紫草膏及其制备方法 | |
CN101518600B (zh) | 一种治疗细菌或真菌性皮肤病的中药组合物及其制备方法 | |
CN105596931A (zh) | 一种治疗皮肤瘙痒症的产品及其制备方法 | |
CN105663928A (zh) | 一种治疗动物皮肤病的药膏及其制备方法 | |
CN103239662A (zh) | 兽用驱虫中药制剂 | |
CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
CN106421392A (zh) | 一种治疗褥疮的中药凝胶剂及其制备方法 | |
CN103372087A (zh) | 一种护肤保健的中药组合物 | |
CN105213584A (zh) | 一种治疗湿疹的中药组合物及其制备方法 | |
CN104524174A (zh) | 一种治疗风湿痹痛的中药组合物及其制备方法 | |
CN105663937A (zh) | 一种用于乳房湿疹的中药制剂及其制备方法 | |
CN108721442B (zh) | 治疗烧烫伤及尿布皮炎的中药组合物、制剂及其制备方法 | |
CN105616647A (zh) | 一种含有艾叶的治疗湿疹的中药组合物及其制备方法 | |
CN113082089A (zh) | 一种治疗皮肤过敏的中药膏剂及其制备方法 | |
CN112807363A (zh) | 温经通络的中药组合物、按摩膏及其制备方法和应用 | |
CN112972557A (zh) | 一种治疗筋骨疼痛的药酒及其制备方法 | |
CN101953951B (zh) | 一种手足保健美容液及其制备方法 | |
CN104800422A (zh) | 一种治疗腹股沟癣的茶树精油及制备方法 | |
CN106728069B (zh) | 一种治疗烫烧伤的祛腐生肌膏 | |
CN104547794A (zh) | 一种治疗骨折的中药组合物 | |
CN107951972A (zh) | 一种治疗奶牛乳房炎的中药组合外擦药物及其制备方法 | |
CN103316260A (zh) | 用于治疗手足癣的按摩膏 | |
CN114831920B (zh) | 一种外用防脱止脱去屑养发生发组合物 | |
CN108066518A (zh) | 一种犬用中药浴液组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |
|
RJ01 | Rejection of invention patent application after publication |